Strengthen Your Product Value Story One Phase At A Time

August 23, 2017

Addressing evidence generation in a phase-specific manner provides mutually reinforcing benefits: trials contribute to the value argument and the value data inform the design of the trials. In this way, utilizing the best available secondary research to inform primary research can reduce the risk of regulatory and reimbursement rejections.

A phase-dependent approach has potential to cut costs by avoiding investing in riskier assets, utilizing secondary evidence for multiple assets (thereby using resources more efficiently), and creating payer value while simultaneously meeting regulatory requirements.

The best way to plan evidence generation for the value story is from the beginning. But if you didn’t do that already, the sooner you start the better.

Previous Flipbook
3 Ways to Reap Benefits_Adaptive Trials
3 Ways to Reap Benefits_Adaptive Trials

Next Video
Agency Readiness – Bob Iser
Agency Readiness – Bob Iser


Speak to a Parexel Biotech expert today!

First Name
Last Name
Job Title
Company Name
Tell us how we can help
Thank you!
Error - something went wrong!